A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease
Latest Information Update: 08 Feb 2023
At a glance
- Drugs Tesevatinib (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Sponsors Kadmon Corporation
- 08 Mar 2022 Status changed from active, no longer recruiting to completed.
- 13 Mar 2020 Planned End Date changed from 10 Aug 2020 to 31 Jan 2022.
- 13 Mar 2020 Planned primary completion date changed from 10 Aug 2020 to 31 Jan 2022.